STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SA

Their core work

STEMMATTERS is a Portuguese biotech SME specializing in regenerative medicine, with hands-on expertise in designing biomaterials and cell-based therapies for tissue repair. Their core work involves engineering hydrogel scaffolds and encapsulation systems that protect and deliver living cells — including stem and progenitor cells — to damaged tissue sites. In H2020 projects they have contributed both as a scientific partner developing nanoengineered scaffolds for spinal cord injury and as a project coordinator building next-generation cell encapsulation platforms for ATMP (Advanced Therapy Medicinal Product) applications. In practice, they bridge the gap between laboratory biomaterial science and the regulatory and manufacturing requirements of cell therapies heading toward clinical use.

What they specialise in

How they've shifted over time

Their earliest H2020 work (NeuroStimSpinal, 2019) positioned them firmly in structural biomaterial science — graphene composites, tissue-engineered scaffolds, and in vitro/in vivo testing of neural progenitor cells for spinal cord repair. By 2020, with NOAHs-ARK, the focus shifted decisively toward therapeutic delivery and clinical translation: cell encapsulation, hydrogels as functional carriers, and the ATMP regulatory framework. This signals a company moving from material innovation toward manufacturable, clinically viable cell therapy products.

STEMMATTERS is moving up the translational ladder — from research-grade biomaterials toward ATMP-compliant cell therapy products, making them increasingly relevant to consortia targeting clinical trials or pharmaceutical partnerships.

How they like to work

STEMMATTERS operates comfortably in both leader and partner roles: they coordinated NOAHs-ARK while participating as a specialist in the larger NeuroStimSpinal consortium. With only 7 unique partners across 4 countries, they favor small, focused consortia rather than large multi-partner networks. This suggests they bring deep specialist input rather than broad coordination infrastructure — a reliable technical contributor who can step up to lead when the project scope matches their core platform.

STEMMATTERS has collaborated with 7 unique partners across 4 European countries, reflecting a compact but genuinely international network. Their geographic footprint is European, with no indication yet of partnerships outside the continent.

What sets them apart

STEMMATTERS occupies a rare niche as a Portuguese biotech SME that combines hands-on biomaterial fabrication with cell therapy know-how and an active eye on ATMP regulatory requirements — a combination that most university labs lack and most large pharma companies outsource. Their size makes them agile enough to act as both partner and coordinator, and their dual expertise in scaffold engineering and cell encapsulation means they can address the full interface between material and biology in a therapeutic product. For consortia targeting regenerative medicine or cell therapy clinical translation, they bring practical, industry-facing capability that complements academic research partners.

Highlights from their portfolio

• NOAHs-ARK
  STEMMATTERS served as project coordinator, demonstrating leadership capacity and full ownership of a cell encapsulation platform explicitly scoped for ATMP regulatory compliance — the most clinically-oriented work in their portfolio.
• NeuroStimSpinal
  Their largest funded project (€403,125), tackling one of the hardest unmet medical needs — spinal cord injury repair — using graphene-composite nanoengineered scaffolds seeded with neural progenitor cells.